Statins and congenital malformations: cohort study this access benefits you. Your matters

ObjeCtive To examine the teratogenic potential of statins. Cohort study. PartiCiPants A cohort of 886 996 completed pregnancies linked to liveborn infants of women enrolled in Medicaid from 2000 to 2007. MethODs We examined the risk of major congenital malformations and organ specific malformations in offspring associated with maternal use of a statin in the first trimester. Propensity score based methods were used to control for potential confounders, including maternal demographic characteristics, obstetric and medical conditions, and use of other drugs. results 1152 (0.13%) women used a statin during the first trimester. In unadjusted analyses, the prevalence of malformations in the offspring of these women was 6.34% compared with 3.55% in those of women who did not use a statin in the first trimester (relative risk 1.79, 95% confidence interval 1.43 to 2.23). Controlling for confounders, particularly pre-existing diabetes, accounted for this increase in risk (1.07, 0.85 to 1.37). for range of sensitivity

[1]  K. Dimopoulos,et al.  Antidepressant use in pregnancy and the risk of cardiac defects. , 2014, The New England journal of medicine.

[2]  G. Koren,et al.  The fetal safety of statins: a systematic review and meta-analysis. , 2014, Journal of obstetrics and gynaecology Canada : JOGC = Journal d'obstetrique et gynecologie du Canada : JOGC.

[3]  Mary K. Kowal,et al.  Validity of maternal and infant outcomes within nationwide Medicaid data , 2014, Pharmacoepidemiology and drug safety.

[4]  N. Wong.  Faculty Opinions recommendation of 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. , 2014 .

[5]  G. Koren,et al.  The transfer of pravastatin in the dually perfused human placenta. , 2013, Placenta.

[6]  Mary K. Kowal,et al.  Harnessing the Medicaid Analytic eXtract (MAX) to Evaluate Medications in Pregnancy: Design Considerations , 2013, PloS one.

[7]  T. Buclin,et al.  Pregnancy outcome following maternal exposure to statins: a multicentre prospective study , 2013, BJOG : an international journal of obstetrics and gynaecology.

[8]  K. Cleary,et al.  Pravastatin for the Prevention of Preeclampsia in High-Risk Pregnant Women , 2013, Obstetrics and gynecology.

[9]  S. Hernández-Díaz,et al.  Algorithms to estimate the beginning of pregnancy in administrative databases , 2013, Pharmacoepidemiology and drug safety.

[10]  Kevin W Cleveland,et al.  Teratogenic Risk of Statins in Pregnancy , 2012, The Annals of pharmacotherapy.

[11]  L. Finer,et al.  Unintended pregnancy in the United States: incidence and disparities, 2006. , 2011, Contraception.

[12]  Ruben A. Smith,et al.  age, Behavioral Risk Factor Surveillance System, , 2011 .

[13]  J. Avorn,et al.  High-dimensional Propensity Score Adjustment in Studies of Treatment Effects Using Health Care Claims Data , 2009, Epidemiology.

[14]  M. Werler,et al.  Maternal exposure to statins and risk for birth defects: A case‐series approach , 2008, American journal of medical genetics. Part A.

[15]  G. Koren,et al.  Prenatal exposure to HMG-CoA reductase inhibitors: effects on fetal and neonatal outcomes. , 2008, Reproductive toxicology.

[16]  Lilah M. Besser,et al.  Diabetes mellitus and birth defects. , 2008, American journal of obstetrics and gynecology.

[17]  R. Platt,et al.  Outpatient use of cardiovascular drugs during pregnancy , 2008, Pharmacoepidemiology and drug safety.

[18]  A. Bérard,et al.  Risk of congenital anomalies in pregnant users of statin drugs , 2007, British journal of clinical pharmacology.

[19]  Lisa Edgerton,et al.  Clinical inquiries. What precautions should we use with statins for women of childbearing age? , 2006, The Journal of family practice.

[20]  M. Cunningham,et al.  Pregnancy outcomes after maternal exposure to simvastatin and lovastatin. , 2005, Birth defects research. Part A, Clinical and molecular teratology.

[21]  M. Muenke,et al.  Gestational exposure to lovastatin followed by cardiac malformation misclassified as holoprosencephaly. , 2005, The New England journal of medicine.

[22]  J. Avorn,et al.  A review of uses of health care utilization databases for epidemiologic research on therapeutics. , 2005, Journal of clinical epidemiology.

[23]  M. Muenke,et al.  Mechanistic and epidemiologic considerations in the evaluation of adverse birth outcomes following gestational exposure to statins , 2004, American journal of medical genetics. Part A.

[24]  A. Gotto,et al.  Update on Statins: 2003 , 2004, Circulation.

[25]  P. Mason.  Update on statins. , 2004, Intensive & critical care nursing.

[26]  M. Muenke,et al.  Central nervous system and limb anomalies in case reports of first-trimester statin exposure. , 2004, The New England journal of medicine.

[27]  S Greenland,et al.  Basic methods for sensitivity analysis of biases. , 1996, International journal of epidemiology.

[28]  W. P. Stephenson,et al.  Postmarketing surveillance of lovastatin and simvastatin exposure during pregnancy. , 1996, Reproductive toxicology.

[29]  M. Khoury,et al.  Human teratogens, prenatal mortality, and selection bias. , 1989, American journal of epidemiology.

[30]  C. Fish.  Drugs in Pregnancy and Lactation: A Reference Guide to Fetal and Neonatal Risk , 1986 .

[31]  M. Graffar.  [Modern epidemiology]. , 1971, Bruxelles medical.